Advertisement

Dextran Low Molecular Weight (Dextran 40), 10% Injection

[26 February 2015]

Products Affected - Description

Dextran 40, Hospira
10% in 500 mL 5% Dextrose, 12 count (NDC 00409-7418-03)
10% in 500 mL 0.9% Sodium Chloride, 12 count (NDC 00409-7419-03)

Reason for the Shortage

Hospira states the reason for the shortage is manufacturing delay.

Available Products

There is insufficient supply for usual ordering.

Estimated Resupply Dates

Hospira has Dextran 40 in 0.9% sodium chloride on back order and the company cannot estimate a release date. Dextran 40 in 5% dextrose is available in limited supply.

Related Shortages

Updated

February 3 and 26, 2015; December 12, October 16, August 13 and 25, July 1, May 27, 2014, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement